New York, NY—February 12, 2026 — On International Urogynecology Day, global attention turns to pelvic
organ prolapse (POP), a highly prevalent yet often overlooked condition affecting up to 50% of women over 50. The day also highlights the growing need for care models that meet women where they are, across healthcare systems worldwide.
organ prolapse (POP), a highly prevalent yet often overlooked condition affecting up to 50% of women over 50. The day also highlights the growing need for care models that meet women where they are, across healthcare systems worldwide.
Pelvic organ prolapse can significantly affect comfort, mobility, and quality of life. Many women with symptomatic prolapse defer surgery, rely on non-surgical management long-term, or are not candidates for invasive procedures due to personal preference, medical comorbidities, or limited access to specialized care. The trend is clear: a substantial population of women are seeking alternatives to traditional surgery.This unmet need underscores demand for safe, effective, minimally invasive solutions with shorter recovery times. At a time when women’s health outcomes are declining globally, expanding access to practical prolapse care has never been more urgent. FEMSelect’s EnPlace® platform is redefining prolapse treatment by enabling durable repair through a minimally invasive approach designed for broad clinical accessibility. The procedure addresses many longstanding barriers to care,including surgical complexity and long recovery times.
Performed in under 30 minutes, a procedure with EnPlace can be offered in outpatient settings such as ambulatory surgery centers, with most patients returning home the same day and managing discomfort with over-the-counter medication.“EnPlace represents a meaningful new option for patients with pelvic organ prolapse,” said Sasha Schrode, CEO, FEMSelect.“For women who are not interested in invasive surgery, it offers a durable, minimally invasive repair approach that can be safely performed in outpatient and low-resource settings, expanding access to care worldwide.”
With more than 6,000 procedures performed globally and four-year data demonstrating a 92% surgical success rate, EnPlace is helping redefine what safe, accessible, and effective prolapse care can look like. By reducing hospital stays, lowering infection risk, and shortening recovery time, this approach is particularly impactful for aging populations and regions with limited resources.
From Israel to Latin America: Expanding Urogynecology Worldwide
FEMSelect’s commitment to advancing urogynecology is reflected in its deliberate international expansion strategy, bringing advanced prolapse care closer to women wherever they live.
EnPlace was first launched in Israel in 2021, where leading urogynecologists helped establish its safety, durability, and real-world clinical utility. In 2026, FEMSelect is expanding into Cyprus and Latin America. Following in-depth market research and distributor identification supported by medikana, the company has secured exclusive distribution partnerships in key markets, including Mexico, Chile, Costa Rica, and Panama.
“Working with medikana has allowed us to listen closely to clinicians and health systems across Latin America,” said Debbie Garner, President, FEMSelect. “Together, we are shaping an approach that brings EnPlace to women in a way that reflects local realities while maintaining the highest standards of safety and effectiveness.”
Supporting Urogynecology Beyond Technology
On International Urogynecology Day, FEMSelect recognizes that advancing urogynecology requires more than innovative devices.Progress depends on education, collaboration, and advocacy across the full continuum of care. By partnering with distributors,health systems, and regional stakeholders, FEMSelect is working to expand equitable access to advanced prolapse treatments—helping ensure women everywhere can live fully, confidently, and without limitation.
About FEMSelect
FEMSelect is a women-led medical technology company dedicated to advancing care for pelvic floor disorders. Its lead technology,EnPlace®, is a minimally invasive, mesh-free system for pelvic organ prolapse supported by strong safety and durability data. Through targeted portfolio expansion, global collaboration, and commercial excellence, FEMSelect is building a leading platform in women’s pelvic health and serving as a committed partner to urogynecologists worldwide.
Media Contact
Stefanie Williamson
631.754.0460
